Entrada Therapeutics, a Boston, MA-based biotechnology company focused on treating devastating diseases through the intracellular delivery of biologics, raised $59m in Series A financing.
The round was co-led by 5AM Ventures and MPM Capital, with participation from Roche Venture Fund, MRL Ventures Fund and Agent Capital.
Led by Dipal Doshi, President and Chief Executive Officer, and Natarajan Sethuraman, Ph.D., Chief Scientific Officer, Entrada Therapeutics treats devastating diseases through the intracellular delivery of biologics. Its technology enables the efficient intracellular delivery of proteins, peptides and nucleic acids, thus allowing for the development of programs across several intracellular target classes.
The first application of the company’s platform is focused on treating a rare and fatal mitochondrial disease with no approved treatments that is caused by mutations in a gene that codes for an intracellular enzyme.
The Series A financing will allow Entrada to advance its lead program into human clinical trials. Additionally, the company plans on broadening its rare, monogenic disease pipeline by identifying and progressing additional intracellular enzyme replacement therapies.
Entrada was funded and incubated within 5AM’s 4:59 Initiative via a seed investment by 5AM Ventures, Roche Venture Fund and MRLV.
FinSMEs
18/12/2018